Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
A Phase II Study of Lapatinib for Brain Metastases in Subjects With ErbB2-Positive Breast Cancer Following Trastuzumab-based Systemic Therapy and Cranial Radiotherapy
Sponsor: Novartis Pharmaceuticals
Listed as NCT00263588, this PHASE2 trial focuses on Neoplasms, Breast and remains completed. Sponsored by Novartis Pharmaceuticals, it has been updated 11 times since 2005, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Completed PHASE2
▶ Show 6 earlier versions
-
Jan 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — Jan 2020 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Mar 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jun 2017 — Mar 2018 [monthly]
Active Not Recruiting PHASE2
-
Feb 2017 — Jun 2017 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Dec 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .